HEAL — Restart Life Sciences Share Price
0.000.00%
Last trade - 00:00- CA$1.66m
- CA$1.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.01 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Restart Life Sciences Corp., formerly Nova Mentis Life Science Corp., is a Canadian life sciences company. The Company is engaged in addressing health challenges with and transformative wellness solutions. Its flagship developments include Autism Spectrum, Health-Related Foods, Canada’s First Psilocybin Clinical Trial for Fragile X Syndrome, Orphan Drug Designation (FDA and EMA), and IP Conveyance Agreement with Ludwig Enterprises Inc. (LUDG). It is at the forefront of developing natural remedies specifically tailored for individuals on the autism spectrum. It focusses is on creating health foods that address the needs of this community. It creates high-quality products that promote overall wellness and support healthier lifestyles. It is developing health-related foods that promote both mind and body wellness for healthy living. Its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the genetic cause of symptoms related to autism spectrum disorder (ASD).
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 27th, 2004
- Public Since
- September 22nd, 2006
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 33,230,355
- Address
- 838 West Hasting Street #700, VANCOUVER, V6C 0A6
- Web
- https://restartlife.co/
- Phone
- +1 7788190244
- Auditors
- Kreston GTA LLP
Upcoming Events for HEAL
Q2 2025 Restart Life Sciences Corp Earnings Release
Similar to HEAL
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
What is the Restart Life Sciences share price?
As of Today at 22:55 UTC, shares in Restart Life Sciences are trading at CA$0.05. This share price information is delayed by 15 minutes.
How has the Restart Life Sciences share price performed this year?
Shares in Restart Life Sciences last closed at CA$0.05 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Restart Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -70.36% over the past year.
What are the analyst and broker recommendations for Restart Life Sciences?
There is no consensus recommendation for this security.
Find out moreWhat is the Restart Life Sciences dividend yield?
Restart Life Sciences does not currently pay a dividend.
Does Restart Life Sciences pay a dividend?
Restart Life Sciences does not currently pay a dividend.
When does Restart Life Sciences next pay dividends?
Restart Life Sciences does not currently pay a dividend.
How do I buy Restart Life Sciences shares?
To buy shares in Restart Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Restart Life Sciences?
As of the previous close price of CA$0.05, shares in Restart Life Sciences had a market capitalisation of CA$1.66m.
Where are Restart Life Sciences shares listed?
Here are the trading details for Restart Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: HEAL
What kind of share is Restart Life Sciences?
Based on an overall assessment of its quality, value and momentum Restart Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Restart Life Sciences share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Restart Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Restart Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -0.59%.
As of the last closing price of CA$0.05, shares in Restart Life Sciences were trading -53.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Restart Life Sciences PE Ratio?
The Restart Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Restart Life Sciences?
Restart Life Sciences' management team is headed by:
- William Rascan - PRE
- Jamie Robinson - CFO
- Steven Feldman - IND
- Stephen Glazer - IND
- Jacqueline Mcconnell - IND